Michael Bromley

Professor and Chair of Division of Evolution, Infection and Genomics, University of Manchester

Chair of AspGRPC

Research in the Bromley Group focuses on the mechanistic basis of fungal pathogenicity with the translational emphasis of developing novel antifungal agents. His research team discovered and exploited mobilisable genetic elements in A. fumigatus which facilitated discovery of numerous essential genes. He is also involved with spin-out company F2G, making major contributions to the identification of potential drug targets in A. fumigatus and advancing these discoveries through target validation to drug development.